SCHEMBL147149

SCHEMBL147149

CCc1csc(C)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfur Dioxide SCHEMBL27499944 0.91 DAO (0.38)
SCHEMBL6437665 0.81 MAPT (0.46)
SCHEMBL146368 0.80
SCHEMBL128743 0.77
SCHEMBL2735670 0.77
SCHEMBL8452184 0.77
SCHEMBL1170262 0.77
SCHEMBL5004859 0.77
SCHEMBL13715998 0.77
SCHEMBL9769261 0.75 PTGS2 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023237504-A1 HSD17B13 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-12-14 WO disclosed
EP-4205565-A1 TOBACCO FILLING MATERIAL AND TOBACCO PRODUCT Japan Tobacco Inc. (JP) 2023-07-05 EP disclosed
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2023-02-09 US disclosed
US-11248073-B2 Manufacturing polymers of thiophene, benzothiophene, and their alkylated derivatives SAUDI ARABIAN OIL COMPANY (SA) 2022-02-15 US disclosed
US-20210130380-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. 2021-05-06 US disclosed
US-10968179-B2 Charged ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2021-04-06 US disclosed
US-20210061763-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE NOCION THERAPEUTICS INC (US) 2021-03-04 US disclosed
EP-3770148-A1 RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2021-01-27 EP disclosed
EP-3760620-A1 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2021-01-06 EP disclosed
EP-2896397-B2 Novel compounds having inhibitory activity against sodium-dependant glucose transporter MITSUBISHI TANABE PHARMA CORP (JP) 2020-10-07 EP disclosed
US-20050209253-A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-09-22 US disclosed
EP-1467997-A1 PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-20 EP disclosed
WO-2004058767-A1 PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-07-15 WO disclosed
EP-1358301-A1 REMOVAL OF SULFUR FROM NAPHTA STREAMS USING HIGH SILICA ZEOLITES ExxonMobil Research and Engineering Company (US) 2003-11-05 EP disclosed
WO-2002053685-A1 REMOVAL OF SULFUR FROM NAPHTA STREAMS USING HIGH SILICA ZEOLITES EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2002-07-11 WO disclosed
US-20020084223-A1 Removal of sulfur from naphtha streams using high silica zeolites EXXONMOBIL RESEARCH & ENGINEERING CO. 2002-07-04 US disclosed
US-4992534-A Anticarcinogenic agents with better water solubility, low toxicity, absorption and stability OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-02-12 US disclosed
US-4748172-A 3-bicyclicpyridinium-methyl cephalosporins ELI LILLY AND COMPANY (US) 1988-05-31 US disclosed
US-4692443-A 3-bicyclicpyridinium-methyl cephalosporins ELI LILLY AND COMPANY (US) 1987-09-08 US disclosed
US-4303689-A Flavoring with pyrazine derivatives FIRMENICH SA (CH) 1981-12-01 US disclosed